Results 11 to 20 of about 1,493,409 (315)
Synthetic lung surfactants containing SP-B and SP-C peptides plus novel phospholipase-resistant lipids or glycerophospholipids [PDF]
Background This study examines the biophysical and preclinical pulmonary activity of synthetic lung surfactants containing novel phospholipase-resistant phosphonolipids or synthetic glycerophospholipids combined with Super Mini-B (S-MB) DATK and/or SP ...
Robert H. Notter +5 more
doaj +4 more sources
Background Severe cases of COVID‐19 often lead to the development of acute respiratory syndrome, a critical condition believed to be caused by the harmful effects of SARS‐CoV‐2 on type II alveolar cells.
Mohammad Navid Bastani, Shahram Jalilian
doaj +2 more sources
This work is focused on the potential use of pulmonary surfactant to deliver full-length recombinant human surfactant protein SP-D (rhSP-D) using the respiratory air-liquid interface as a shuttle.
Cristina García-Mouton +5 more
doaj +2 more sources
Contact-angle hysteresis induced by pulmonary surfactants
Hydrophilic surfaces in the form of glass slides have been coated with monolayers of three of the major components of pulmonary surfactant, and the wettabilities of the resulting surfaces have been studied by applying a single drop of saline.
B. A. Hills
core +2 more sources
A Comparison of the Effect of Beractant (Beracsurf) and Proctant Alpha (Curosurf) in Neonatal Respiratory Distress: A Randomized Controlled Trial [PDF]
Background: Surfactant treatment has revolutionized the management of respiratory distress syndrome (RDS) in preterm infants. The present study compared the effectiveness and adverse effects of two natural surfactants, Beracsurf and Curosurf, in ...
Khadijeh Sadat Najib +3 more
doaj +2 more sources
The influence of natural pulmonary surfactant on the efficacy of siRNA-loaded dextran nanogels [PDF]
Aim: Topical administration of siRNA nanocarriers is a promising approach in the treatment of pulmonary disorders. Pulmonary surfactant, covering the entire alveolar surface of mammalian lungs, will be one of the first interfaces that siRNA nanocarriers ...
De Smedt, Stefaan +4 more
core +2 more sources
Pulmonary tuberculosis is associated with a year-long chemotherapy, poor alveolar drug levels, drug-related systemic toxicity, and patient noncompliance. In this study, exogenous pulmonary surfactant is proposed as a drug carrier for antitubercular drugs.
G Chimote, Rinti Banerjee
exaly +2 more sources
Introduction. Despite the fact that clinical studies of pulmonary surfactants conducted over many years have demonstrated their efficacy for the treatment of acute respiratory distress syndrome (ARDS) which led to their approval for use inRussia ...
O. A. Rosenberg
doaj +3 more sources
Reasonable suspicion has accumulated that inhaled nano-scale particulate matter influences the biophysical function of the pulmonary surfactant system.
Seeger, Werner +9 more
core +2 more sources
Lipid-Laden Macrophages in Pulmonary Diseases
Pulmonary surfactants play a crucial role in managing lung lipid metabolism, and dysregulation of this process is evident in various lung diseases. Alternations in lipid metabolism lead to pulmonary surfactant damage, resulting in hyperlipidemia in ...
Yin Zhu +3 more
doaj +2 more sources

